Clinical Trial Update: Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating neoadjuvant ADT plus darolutamide with pembrolizumab, followed by adjuvant pembrolizumab, in molecularly stratified high-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Androgen deprivation therapy (Androgen deprivation therapy)
• Darolutamide (darolutamide)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Prostate Cancer, High-risk Prostate Cancer | Phase 2 | Status: RECRUITING